LTIP266A - Process for the preparation of a standardized human von willebrand factor concentrate for therapeutical use - Google Patents
Process for the preparation of a standardized human von willebrand factor concentrate for therapeutical useInfo
- Publication number
- LTIP266A LTIP266A LTIP266A LTIP266A LTIP266A LT IP266 A LTIP266 A LT IP266A LT IP266 A LTIP266 A LT IP266A LT IP266 A LTIP266 A LT IP266A LT IP266 A LTIP266 A LT IP266A
- Authority
- LT
- Lithuania
- Prior art keywords
- preparation
- von willebrand
- willebrand factor
- standardized human
- human von
- Prior art date
Links
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 title 1
- 239000012141 concentrate Substances 0.000 title 1
- 229940034998 human von willebrand factor Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9102804A FR2673632A1 (en) | 1991-03-08 | 1991-03-08 | PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP266A true LTIP266A (en) | 1994-07-15 |
| LT3175B LT3175B (en) | 1995-02-27 |
Family
ID=9410505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP266A LT3175B (en) | 1991-03-08 | 1992-12-30 | Process for the preparation of a standardized human von willebrand factor concentrate for therapeutical use |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5408039A (en) |
| EP (1) | EP0503991B1 (en) |
| JP (1) | JP3435668B2 (en) |
| AT (1) | AT407115B (en) |
| AU (1) | AU645172B2 (en) |
| BE (1) | BE1004178A3 (en) |
| BR (1) | BR9200770A (en) |
| CA (1) | CA2062340C (en) |
| CZ (1) | CZ283633B6 (en) |
| DE (2) | DE69227055T2 (en) |
| DK (1) | DK0503991T3 (en) |
| EE (1) | EE03057B1 (en) |
| EG (1) | EG20300A (en) |
| ES (1) | ES2121830T3 (en) |
| FI (1) | FI106721B (en) |
| FR (1) | FR2673632A1 (en) |
| HU (1) | HU215098B (en) |
| IL (1) | IL101043A (en) |
| IT (1) | IT1256692B (en) |
| LT (1) | LT3175B (en) |
| NL (1) | NL300394I1 (en) |
| NO (1) | NO301278B1 (en) |
| NZ (1) | NZ241701A (en) |
| PL (1) | PL168353B1 (en) |
| RU (1) | RU2088590C1 (en) |
| SA (1) | SA92120446B1 (en) |
| SK (1) | SK279533B6 (en) |
| UA (1) | UA27732C2 (en) |
| ZA (1) | ZA921430B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4435485C1 (en) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Process for obtaining high-purity von Willebrand factor |
| DE4435392B4 (en) * | 1994-10-04 | 2008-02-07 | Immuno Ag | Method for separating vWF into high molecular weight vWF and low molecular weight vWF |
| DE4437544A1 (en) * | 1994-10-20 | 1996-04-25 | Behringwerke Ag | Use of vWF-containing concentrates as combination therapy for therapy with antithrombotics and fibrinolytics |
| US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
| US6005077A (en) * | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| DE19616540A1 (en) * | 1995-11-10 | 1997-05-15 | Immuno Ag | Use of von Willebrand factor and pharmaceutical preparation |
| AT403764B (en) | 1996-03-15 | 1998-05-25 | Immuno Ag | STABLE FACTOR VIII / VWF COMPLEX |
| US6068838A (en) * | 1996-04-29 | 2000-05-30 | Baxter Aktiengesellschaft | Purified multimerase |
| AT404358B (en) | 1997-02-04 | 1998-11-25 | Immuno Ag | METHOD FOR CHROMATOGRAPHIC CLEANING OR FRACTIONATION OF VON WILLEBRAND FACTOR FROM A VWF-CONTAINING MATERIAL |
| AT405403B (en) | 1997-02-27 | 1999-08-25 | Immuno Ag | CLEANING OF WILLEBRAND FACTOR BY CATION EXCHANGER CHROMATOGRAPHY |
| AT405485B (en) * | 1997-05-28 | 1999-08-25 | Immuno Ag | A PHARMACEUTICAL PREPARATION CONTAINING THE VWF PROPEPTIDE |
| PT2193809E (en) | 1999-02-22 | 2015-08-24 | Baxter Int | Albumin-free factor viii formulations |
| EP1148063A1 (en) * | 2000-04-18 | 2001-10-24 | Octapharma AG | Composition containing hemostatic activ vWF and process for its preparation |
| RU2200028C2 (en) * | 2000-06-20 | 2003-03-10 | Кировский НИИ гематологии и переливания крови | Method for filling puncture canal after performing diagnostic endoscopic hepatic puncture biopsy in patients suffering from hemophilia a |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| FR2874216B1 (en) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | PROCESS FOR THE PREPARATION OF A VON WILLEBRAND FACTOR CONCENTRATE (FVW) BY CHROMATOGRAPHIC AND CONCENTRATED FVW SO LIKELY TO BE OBTAINED |
| DE102004044419B4 (en) | 2004-09-14 | 2010-04-15 | Biotest Ag | Process for the purification of a von Willebrand factor by means of hydroxylapatite continuous chromatography |
| DE102004044429B4 (en) * | 2004-09-14 | 2009-04-30 | Biotest Ag | Process for the preparation of a composition containing von Willebrand factor |
| ITLU20070007A1 (en) * | 2007-05-07 | 2008-11-08 | Kedrion Spa | CHROMATOGRAPHIC PROCESS FOR OBTAINING A FVIII / VWF COMPLEX WITH DIFFERENT RELATIONSHIPS BETWEEN THE TWO PROTEINS TO BE USED IN THE HEMOPHILIA A THERAPY AND IN VON WILLEBRAND'S DISEASE. |
| EP2486936A1 (en) | 2007-06-13 | 2012-08-15 | CSL Behring GmbH | A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders |
| FR2920429B1 (en) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | PROCESS FOR PURIFYING FACTOR VIII AND VON WILLEBRAND FACTOR |
| EP2073015A1 (en) | 2007-12-21 | 2009-06-24 | CSL Behring GmbH | Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function |
| US20100273206A1 (en) * | 2007-12-21 | 2010-10-28 | Manfred Rauh | Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function |
| DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| BRPI0921429B1 (en) * | 2008-11-07 | 2022-07-12 | Takeda Pharmaceutical Company Limited | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION, AND METHOD FOR PREPARING A STABLE LYOPHILIZED FACTOR |
| IT1396528B1 (en) | 2009-01-19 | 2012-12-14 | Kedrion Spa | NEW HIGHLY SELECTIVE PURIFICATION PROCESS OF TWO PLASMATIC PROTEINS: VON WILLEBRAND FACTOR (VWF) AND FIBRONECTIN (FN). |
| AU2010284977A1 (en) | 2009-08-20 | 2012-03-29 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| AU2011343813B2 (en) | 2010-12-15 | 2015-05-21 | Takeda Pharmaceutical Company Limited | Eluate collection using conductivity gradient |
| KR20140083035A (en) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii |
| KR20140083036A (en) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| PL2814502T3 (en) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
| ES2657291T3 (en) | 2013-04-22 | 2018-03-02 | Csl Ltd. | A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge |
| ES2693380T3 (en) | 2013-11-08 | 2018-12-11 | Csl Limited | New method to concentrate the von Willebrand factor or complexes of this |
| EP3164150B1 (en) | 2014-07-02 | 2020-11-04 | CSL Behring Lengnau AG | Modified von willebrand factor |
| US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| FR3034669B1 (en) | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | NEW USE OF THE VON WILLEBRAND FACTOR |
| EP3362464B1 (en) * | 2015-10-15 | 2021-04-28 | Plasma Technologies LLC | Methods for extracting proteins from blood plasma |
| RU2018128582A (en) | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | MUTED CROPPED VILLEBRAND BACKGROUND FACTOR |
| DK3400238T3 (en) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | MUTERATED BY WILLEBRAND FACTOR |
| CN105622746A (en) * | 2016-02-04 | 2016-06-01 | 江西博雅生物制药股份有限公司 | Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII |
| CN105622747A (en) * | 2016-02-04 | 2016-06-01 | 江西博雅生物制药股份有限公司 | vWF (von Willebrand factor) activity protection fluid |
| CN105541997A (en) * | 2016-02-04 | 2016-05-04 | 江西博雅生物制药股份有限公司 | Preparation process of high-purity and high-activity von Willebrand factors |
| EP3488858A1 (en) | 2017-11-27 | 2019-05-29 | Laboratoire Français du Fractionnement et des Biotechnologies | A von willebrand factor composition for use in treating a pathology mediated by angiogenesis |
| CN114249812B (en) * | 2020-09-22 | 2023-09-15 | 四川远大蜀阳药业有限责任公司 | Method for reducing IgM content in vWF (vWF) product |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61166542A (en) * | 1985-01-18 | 1986-07-28 | Hitachi Chem Co Ltd | Photosensitive composition |
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US5006642A (en) * | 1987-06-29 | 1991-04-09 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Purification of von Willebrand Factor by affinity chromatography |
| FR2632309B1 (en) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | PROCESS FOR THE CHROMATOGRAPHIC PURIFICATION OF PROTEINS, PARTICULARLY FACTOR VIII, AND THE PRODUCTS OBTAINED |
-
1991
- 1991-03-08 FR FR9102804A patent/FR2673632A1/en active Granted
-
1992
- 1992-02-19 AU AU11131/92A patent/AU645172B2/en not_active Expired
- 1992-02-24 IL IL10104392A patent/IL101043A/en not_active IP Right Cessation
- 1992-02-24 NZ NZ241701A patent/NZ241701A/en not_active IP Right Cessation
- 1992-02-26 CZ CS92568A patent/CZ283633B6/en not_active IP Right Cessation
- 1992-02-26 SK SK568-92A patent/SK279533B6/en not_active IP Right Cessation
- 1992-02-26 ZA ZA921430A patent/ZA921430B/en unknown
- 1992-02-27 EP EP92400505A patent/EP0503991B1/en not_active Expired - Lifetime
- 1992-02-27 DK DK92400505T patent/DK0503991T3/en active
- 1992-02-27 DE DE69227055T patent/DE69227055T2/en not_active Expired - Lifetime
- 1992-02-27 DE DE122009000034C patent/DE122009000034I2/en active Active
- 1992-02-27 ES ES92400505T patent/ES2121830T3/en not_active Expired - Lifetime
- 1992-03-03 JP JP08030592A patent/JP3435668B2/en not_active Expired - Lifetime
- 1992-03-04 BE BE9200215A patent/BE1004178A3/en not_active IP Right Cessation
- 1992-03-05 CA CA002062340A patent/CA2062340C/en not_active Expired - Lifetime
- 1992-03-05 NO NO920867A patent/NO301278B1/en not_active IP Right Cessation
- 1992-03-06 RU SU925011041A patent/RU2088590C1/en active
- 1992-03-06 FI FI920992A patent/FI106721B/en active
- 1992-03-06 PL PL92293738A patent/PL168353B1/en unknown
- 1992-03-06 AT AT0043692A patent/AT407115B/en not_active IP Right Cessation
- 1992-03-06 BR BR929200770A patent/BR9200770A/en not_active Application Discontinuation
- 1992-03-06 US US07/846,852 patent/US5408039A/en not_active Expired - Lifetime
- 1992-03-06 HU HU9200767A patent/HU215098B/en not_active IP Right Cessation
- 1992-03-06 IT ITTO920189A patent/IT1256692B/en active IP Right Grant
- 1992-03-07 EG EG13192A patent/EG20300A/en active
- 1992-04-18 SA SA92120446A patent/SA92120446B1/en unknown
- 1992-12-30 LT LTIP266A patent/LT3175B/en not_active IP Right Cessation
-
1993
- 1993-05-21 UA UA93002713A patent/UA27732C2/en unknown
-
1994
- 1994-05-23 EE EE9400004A patent/EE03057B1/en not_active IP Right Cessation
-
2009
- 2009-07-07 NL NL300394C patent/NL300394I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTIP266A (en) | Process for the preparation of a standardized human von willebrand factor concentrate for therapeutical use | |
| NZ234377A (en) | Multi-layered therapeutic systems containing methanediphosphonic acid derivatives | |
| EP0367285A3 (en) | Disposable resuscitator | |
| DE3461466D1 (en) | 3',4',5,7-tetrahydroxyflavone derivatives, process for their preparation and their therapeutical use | |
| EP0363953A3 (en) | Preparation of catheter | |
| DE3369143D1 (en) | Highly purified human antihemophilic factor and method for the preparation thereof | |
| AU7036787A (en) | Stepping staff | |
| IL91162A0 (en) | Regulated transformer rectifier unit | |
| GR861527B (en) | Preparation process for therapeutical agents | |
| HU896694D0 (en) | New medicine form | |
| EP0182766A3 (en) | A surgical drape | |
| GB2225953B (en) | "tracheostomy devices" | |
| DE3466539D1 (en) | 4'-flavonecarboxylic acids, process for their preparation and their therapeutical use | |
| EP0551084A3 (en) | Human antithrombin-iii preparation | |
| AU106669S (en) | Disposable resuscitator | |
| DE3467092D1 (en) | Patient's positioning table | |
| ZA90692B (en) | A pharmaceutical preparation in the treatment of tonsillitis | |
| GR861655B (en) | Preparation process for a medicine used for the psoriasis treatment and application therefor | |
| HU905823D0 (en) | Medical preparations | |
| HU896683D0 (en) | Process for the preparation of new therapeutical preparations | |
| EP0373919A3 (en) | Process for the preparation of 2'-deoxy-beta-adenosine | |
| RU1833741C (en) | Medicine glue | |
| EP0324111A3 (en) | Process for the preparation of cycloaliphatic aldehydes | |
| HU911524D0 (en) | Medical preparation "a-regeneral" | |
| GB8827194D0 (en) | Two section"bo/staff" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC9A | Transfer of patents |
Owner name: THE LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES Effective date: 20090511 |
|
| TC9A | Change of representative |
Representative=s name: ZABOLIENE, REDA, LT |
|
| MM9A | Lapsed patents |
Effective date: 20091230 |